{"corpus_id":3202878,"paper_sha":"c0cebaee080242a5c1a5d570d2692b703315cd63","doi":"10.1016/j.virol.2011.07.004","arxiv_id":null,"pmid":21802104,"pmcid":null,"mag_id":2082281440,"dblp_id":null,"acl_id":null,"title":"Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C.","year":2011,"publication_date":"2011-09-01","venue":"Virology","journal":{"name":"Virology","pages":"\n          253-8\n        ","volume":"417 2"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle"],"pubmed_pub_types":["Journal Article","Research Support, N.I.H., Extramural","Research Support, Non-U.S. Gov't"],"s2_fields_of_study":["Biology","Medicine"],"reference_count":37,"citation_count":57,"influential_citation_count":2,"is_open_access":false,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Adenine","mj":false,"qs":[{"q":"analogs & derivatives","mj":true,"ui":"Q000031"},{"q":"pharmacology","mj":false,"ui":"Q000494"}],"ui":"D000225"},{"d":"Algal Proteins","mj":false,"qs":[{"q":"pharmacology","mj":true,"ui":"Q000494"}],"ui":"D020418"},{"d":"Anti-HIV Agents","mj":false,"qs":[{"q":"pharmacology","mj":true,"ui":"Q000494"}],"ui":"D019380"},{"d":"CD4-Positive T-Lymphocytes","mj":false,"qs":[{"q":"virology","mj":false,"ui":"Q000821"}],"ui":"D015496"},{"d":"Cells, Cultured","mj":false,"ui":"D002478"},{"d":"Cyclohexanes","mj":false,"qs":[{"q":"pharmacology","mj":true,"ui":"Q000494"}],"ui":"D003510"},{"d":"Drug Synergism","mj":true,"ui":"D004357"},{"d":"Enfuvirtide","mj":false,"ui":"D000077560"},{"d":"Genotype","mj":false,"ui":"D005838"},{"d":"HIV Envelope Protein gp41","mj":false,"qs":[{"q":"pharmacology","mj":true,"ui":"Q000494"}],"ui":"D015700"},{"d":"HIV-1","mj":false,"qs":[{"q":"classification","mj":false,"ui":"Q000145"},{"q":"drug effects","mj":true,"ui":"Q000187"},{"q":"genetics","mj":false,"ui":"Q000235"}],"ui":"D015497"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Lectins","mj":false,"qs":[{"q":"pharmacology","mj":true,"ui":"Q000494"}],"ui":"D037102"},{"d":"Leukocytes, Mononuclear","mj":false,"qs":[{"q":"virology","mj":false,"ui":"Q000821"}],"ui":"D007963"},{"d":"Maraviroc","mj":false,"ui":"D000077592"},{"d":"Microbial Sensitivity Tests","mj":false,"ui":"D008826"},{"d":"Organophosphonates","mj":false,"qs":[{"q":"pharmacology","mj":true,"ui":"Q000494"}],"ui":"D063065"},{"d":"Peptide Fragments","mj":false,"qs":[{"q":"pharmacology","mj":true,"ui":"Q000494"}],"ui":"D010446"},{"d":"Plant Lectins","mj":false,"ui":"D037121"},{"d":"Tenofovir","mj":false,"ui":"D000068698"},{"d":"Triazoles","mj":false,"qs":[{"q":"pharmacology","mj":true,"ui":"Q000494"}],"ui":"D014230"}],"chemicals":[{"n":"Algal Proteins","ui":"D020418","reg":"0"},{"n":"Anti-HIV Agents","ui":"D019380","reg":"0"},{"n":"Cyclohexanes","ui":"D003510","reg":"0"},{"n":"HIV Envelope Protein gp41","ui":"D015700","reg":"0"},{"n":"Lectins","ui":"D037102","reg":"0"},{"n":"Organophosphonates","ui":"D063065","reg":"0"},{"n":"Peptide Fragments","ui":"D010446","reg":"0"},{"n":"Plant Lectins","ui":"D037121","reg":"0"},{"n":"Triazoles","ui":"D014230","reg":"0"},{"n":"Enfuvirtide","ui":"D000077560","reg":"19OWO1T3ZE"},{"n":"Tenofovir","ui":"D000068698","reg":"99YXE507IL"},{"n":"Adenine","ui":"D000225","reg":"JAC85A2161"},{"n":"Maraviroc","ui":"D000077592","reg":"MD6P741W8A"},{"n":"griffithsin protein, Griffithsia","ui":"C499654","reg":"Z8PX5UX50U"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":null,"s2_open_access_landing_url":null,"s2_open_access_license":null,"s2_open_access_status":null,"pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"Griffithsin (GRFT) is possibly the most potent anti-HIV peptide found in natural sources. Due to its potent and broad-spectrum antiviral activity and unique safety profile it has great potential as topical microbicide component. Here, we evaluated various combinations of GRFT against HIV-1 clade B and clade C isolates in primary peripheral blood mononuclear cells (PBMCs) and in CD4(+) MT-4 cells. In all combinations tested, GRFT showed synergistic activity profile with tenofovir, maraviroc and enfuvirtide based on the median effect principle with combination indices (CI) varying between 0.34 and 0.79 at the calculated EC(95) level. Furthermore, the different glycosylation patterns on the viral envelope of clade B and clade C gp120 had no observable effect on the synergistic interactions. Overall, we can conclude that the evaluated two-drug combination increases their antiviral potency and supports further clinical investigations in pre-exposure prophylaxis for GRFT combinations in the context of HIV-1 clade C infection.","claims":[{"public_id":"cl_b2d7bfbbff3f5292e9cfcfeb9a6054b9","status":"active","text":"Different glycosylation patterns on the viral envelope of clade B and clade C gp120 had no observable effect on the synergistic interactions of GRFT combinations.","confidence":0.9,"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":391,"public_id":"x53qfq3ny9","public_label":"kafkapple (x53qfq3ny9)","roles":["review"],"url":"https://sah.borca.ai/u/x53qfq3ny9"}],"url":"https://sah.borca.ai/claims/cl_b2d7bfbbff3f5292e9cfcfeb9a6054b9"},{"public_id":"cl_397583a6595e5e403e721963d01baceb","status":"active","text":"Griffithsin (GRFT) showed synergistic activity profile with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C isolates in primary PBMCs and CD4+ MT-4 cells, with combination indices between 0.34 and 0.79 at the EC(95) level.","confidence":0.95,"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":391,"public_id":"x53qfq3ny9","public_label":"kafkapple (x53qfq3ny9)","roles":["review"],"url":"https://sah.borca.ai/u/x53qfq3ny9"}],"url":"https://sah.borca.ai/claims/cl_397583a6595e5e403e721963d01baceb"},{"public_id":"cl_331640052d105d446a4191ea3d10521b","status":"active","text":"The evaluated two-drug combinations of GRFT with tenofovir, maraviroc, or enfuvirtide increase antiviral potency and support further clinical investigations in pre-exposure prophylaxis for GRFT combinations in HIV-1 clade C infection.","confidence":0.85,"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":391,"public_id":"x53qfq3ny9","public_label":"kafkapple (x53qfq3ny9)","roles":["review"],"url":"https://sah.borca.ai/u/x53qfq3ny9"}],"url":"https://sah.borca.ai/claims/cl_331640052d105d446a4191ea3d10521b"}],"concepts":[{"public_id":"co_08f7b5e7508cba9cea32983da5562044","status":"active","name":"synergistic interactions","description":"The combined effect of GRFT with antiretroviral drugs showing greater potency than individual agents.","types":["pharmacological interaction"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":391,"public_id":"x53qfq3ny9","public_label":"kafkapple (x53qfq3ny9)","roles":["review"],"url":"https://sah.borca.ai/u/x53qfq3ny9"}],"url":"https://sah.borca.ai/concepts/co_08f7b5e7508cba9cea32983da5562044"},{"public_id":"co_0cb17d4bda13f983e35f26f144aa18a9","status":"active","name":"griffithsin","description":"A potent anti-HIV peptide from natural sources evaluated as a topical microbicide component.","types":["peptide","antiviral agent"],"aliases":["GRFT"],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":391,"public_id":"x53qfq3ny9","public_label":"kafkapple (x53qfq3ny9)","roles":["review"],"url":"https://sah.borca.ai/u/x53qfq3ny9"}],"url":"https://sah.borca.ai/concepts/co_0cb17d4bda13f983e35f26f144aa18a9"},{"public_id":"co_2680909986c3429df38344aa78d2ca0f","status":"active","name":"gp120","description":"The viral envelope glycoprotein of HIV-1 whose glycosylation patterns were compared between clade B and clade C.","types":["viral protein"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":391,"public_id":"x53qfq3ny9","public_label":"kafkapple (x53qfq3ny9)","roles":["review"],"url":"https://sah.borca.ai/u/x53qfq3ny9"}],"url":"https://sah.borca.ai/concepts/co_2680909986c3429df38344aa78d2ca0f"},{"public_id":"co_2888969919751de2dbd419ec94daa6ea","status":"active","name":"maraviroc","description":"An antiretroviral drug used in combination with griffithsin against HIV-1.","types":["antiretroviral drug"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":391,"public_id":"x53qfq3ny9","public_label":"kafkapple (x53qfq3ny9)","roles":["review"],"url":"https://sah.borca.ai/u/x53qfq3ny9"}],"url":"https://sah.borca.ai/concepts/co_2888969919751de2dbd419ec94daa6ea"},{"public_id":"co_2c1ad54e7128cb638ea55c76d0d95111","status":"active","name":"tenofovir","description":"An antiretroviral drug used in combination with griffithsin against HIV-1.","types":["antiretroviral drug"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":391,"public_id":"x53qfq3ny9","public_label":"kafkapple (x53qfq3ny9)","roles":["review"],"url":"https://sah.borca.ai/u/x53qfq3ny9"}],"url":"https://sah.borca.ai/concepts/co_2c1ad54e7128cb638ea55c76d0d95111"},{"public_id":"co_58ac6a2917d86f879fb3300c59a56fe2","status":"active","name":"HIV-1 clade C","description":"A subtype of HIV-1 against which griffithsin combinations were tested in primary PBMCs and CD4+ MT-4 cells.","types":["viral subtype"],"aliases":["clade C"],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":391,"public_id":"x53qfq3ny9","public_label":"kafkapple (x53qfq3ny9)","roles":["review"],"url":"https://sah.borca.ai/u/x53qfq3ny9"}],"url":"https://sah.borca.ai/concepts/co_58ac6a2917d86f879fb3300c59a56fe2"},{"public_id":"co_672a7f06f699b53e7d518a2419c9cf17","status":"active","name":"glycosylation patterns","description":"Different glycosylation patterns on the viral envelope gp120 of clade B and clade C that did not affect synergistic interactions.","types":["structural feature"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":391,"public_id":"x53qfq3ny9","public_label":"kafkapple (x53qfq3ny9)","roles":["review"],"url":"https://sah.borca.ai/u/x53qfq3ny9"}],"url":"https://sah.borca.ai/concepts/co_672a7f06f699b53e7d518a2419c9cf17"},{"public_id":"co_88ff3f5b7310f5d581740b652d1b3d2c","status":"active","name":"enfuvirtide","description":"An antiretroviral drug used in combination with griffithsin against HIV-1.","types":["antiretroviral drug"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":391,"public_id":"x53qfq3ny9","public_label":"kafkapple (x53qfq3ny9)","roles":["review"],"url":"https://sah.borca.ai/u/x53qfq3ny9"}],"url":"https://sah.borca.ai/concepts/co_88ff3f5b7310f5d581740b652d1b3d2c"},{"public_id":"co_93925334864d4f818eb194e019f177f8","status":"active","name":"combination indices","description":"Quantitative measures of synergy based on the median effect principle, ranging from 0.34 to 0.79 at the EC(95) level.","types":["metric"],"aliases":["CI"],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":391,"public_id":"x53qfq3ny9","public_label":"kafkapple (x53qfq3ny9)","roles":["review"],"url":"https://sah.borca.ai/u/x53qfq3ny9"}],"url":"https://sah.borca.ai/concepts/co_93925334864d4f818eb194e019f177f8"},{"public_id":"co_a2732116095649d357e52000bdfe27eb","status":"active","name":"pre-exposure prophylaxis","description":"A preventive strategy for which GRFT combinations are proposed for further clinical investigation against HIV-1 clade C infection.","types":["prevention strategy"],"aliases":["PrEP"],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":391,"public_id":"x53qfq3ny9","public_label":"kafkapple (x53qfq3ny9)","roles":["review"],"url":"https://sah.borca.ai/u/x53qfq3ny9"}],"url":"https://sah.borca.ai/concepts/co_a2732116095649d357e52000bdfe27eb"}],"external_ids":{"DOI":"10.1016/j.virol.2011.07.004","ArXiv":null,"PubMed":21802104,"PubMedCentral":null,"MAG":2082281440,"DBLP":null,"ACL":null},"open_access":{"is_open_access":false,"pdf_url":null,"landing_url":"https://sah.borca.ai/papers/3202878","source":null,"pdf_url_source":null,"license":null,"reason":"pdf_url_not_indexed"},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":636681,"paper_uid":"b340fef1-f270-4ac1-bb8d-cc5277e897ca","canonical_identity":{"paper_id":636681,"paper_uid":"b340fef1-f270-4ac1-bb8d-cc5277e897ca","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/3202878"}